T
TALON THERAPEUTICS
Biopharmaceutical company offering products for clinical development
About TALON THERAPEUTICS
Talon Therapeutics, Inc., originally established as Hana Biosciences in 2002, was a biopharmaceutical firm concentrated on the development and commercialization of treatments for unmet medical needs in cancer care. The company was initially founded as Hana Biosciences by Paramount BioCapital Investments and Dr. Mark J. Ahn, who served as the founding President and CEO. Dr. Ahn brought experience from executive roles at Genentech and Bristol-Myers Squibb. In 2007, Dr. Steven R. Deitcher took over as President and CEO. Dr. Deitcher, a hematologist and medical oncologist who previously led hematology at the Cleveland Clinic, guided the company through a pivotal phase of its growth, including the approval of its lead drug and its eventual sale.
The company's business model centered on acquiring, developing, and commercializing novel oncology product candidates. Its primary market was cancer therapeutics, specifically focusing on hematology and oncology. The firm's strategy involved advancing a pipeline of drugs that could offer improved therapeutic benefits over existing treatments. This culminated in the 2013 acquisition of Talon by Spectrum Pharmaceuticals, a deal valued at approximately $11.3 million in upfront cash plus up to $195 million in potential future milestone payments. The acquisition provided Spectrum with an FDA-approved product that complemented its existing oncology franchise.
Talon's lead product was Marqibo® (vincristine sulfate liposome injection), which received accelerated FDA approval for treating adult patients with Philadelphia chromosome-negative Acute Lymphoblastic Leukemia (ALL) in second or greater relapse. Marqibo utilized a proprietary Optisome encapsulation technology, a liposomal drug delivery method designed to increase a drug's circulation time and target it more effectively to tumors. This formulation of the widely-used chemotherapy agent vincristine was intended to enable higher potency dosing without a proportional increase in toxicity. The company's pipeline also included other candidates like Menadione Topical Lotion, aimed at treating skin toxicities from certain cancer therapies, and other Optisome-encapsulated drugs such as Brakiva and Alocrest for various solid tumors.
Source: Dealroom company dataNews
Open roles
TALON THERAPEUTICS in the South San Francisco ecosystem
The TALON THERAPEUTICS office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about TALON THERAPEUTICS on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TALON THERAPEUTICS on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

